Dear readers of, please forgive the disruption. needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find useful, please take a minute and support with your donation. Thank you!

Since 01.06.2021 is supported by the non-profit ADxS e.V..

$16307 of $36850 - as of 2023-08-31
Header Image
Reboxitin for ADHD


Reboxitin for ADHD

Reboxitin is a norepinephrine reuptake inhibitor, alongside weak serotonin reuptake inhibition.

Trade names: Edronax (D, CH, A), Solcenx (D)

Reboxitin is a noradrenergic drug that has been reported to be effective in ADHD. As an antidepressant, as it was actually intended, it was probably quite unsuccessful.

The updated European Consensus on the Diagnosis and Treatment of ADHD (2018) names reboxitine as a possible alternative to atomoxetine for ADHD.1

There is evidence of efficacy of reboxitin in ADHD. However, there are only a few controlled studies.Reboxitin could be used primarily in adults without comorbidities.23

In Germany, Reboxitin is not reimbursed by health insurance companies.